News | Heart Failure | March 03, 2023

Rutgers Researchers Use Artificial Intelligence to Predict Cardiovascular Disease

Machine learning can be used to help clinicians with early diagnosis

Machine learning can be used to help clinicians with early diagnosis

Getty Images


March 3, 2023 —  Researchers may be able to predict cardiovascular disease – such as atrial fibrillation and heart failure – in patients by using artificial intelligence (AI) to examine the genes in their DNA, according to a new Rutgers study. 

“With the successful execution of our model, we predicted the association of highly significant cardiovascular disease genes tied to demographic variables like race, gender and age.” said Zeeshan Ahmed, a core faculty member at the Rutgers Institute for Health, Health Care Policy and Aging Research (IFH) and lead author of the study, published in Genomics. 

According to the World Health Organization, cardiovascular disease is the leading cause of death globally, yet it is estimated that more than 75 percent of premature cardiovascular disease is preventable. Atrial fibrillation and heart failure contribute to about 45 percent of all cardiovascular disease deaths. 

Despite significant advancements in cardiovascular disease diagnostics, prevention and treatment, about half of the affected patients reportedly die within five years of receiving a diagnosis because of a variety of reasons. including genetic and environmental factors. Researchers said the use of AI and machine learning can accelerate our ability to identify genes that have important implications for cardiovascular disease, which can lead to improvements in diagnoses and treatment. 

Researchers from IFH analyzed healthy patients and patients diagnosed with cardiovascular disease and used AI and machine-learning models to investigate the genes known to be associated with the most common manifestations of cardiovascular disease, including atrial fibrillation and heart failure

They identified a group of genes that were significantly associated with having cardiovascular disease. Researchers also found significant differences among race, gender and age factors based on the cardiovascular disease. While age and gender factors correlated to heart failure, age and race factors correlated to atrial fibrillation. For example, in the patients examined, the older the patient, the more likely they were to have a cardiovascular disease. 

“Timely understanding and precise treatment of cardiovascular disease will ultimately benefit millions of individuals by reducing the high risk for mortality and improving the quality of life,” said Ahmed, who is an assistant professor with the Department of Medicine at Rutgers Robert Wood Johnson Medical School

Researchers said future research should extend this approach by analyzing the full set of genes in patients with cardiovascular disease which may reveal important biomarkers and risk factors associated with the cardiovascular disease susceptibility. 


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now